China's ministry of commerce conditionally approved Becton Dickinson and Co.'s acquisition of C. R. Bard Inc., Reuters reported.
Becton Dickinson is required to sell its global core needle biopsy devices business and a tissue marker product under development as part of the approval.
Becton Dickinson said it plans to sell the soft tissue core needle biopsy product line to Merit Medical pending approval from Chinese authorities.
The U.S. Federal Trade Commission recently approved the $24 billion acquisition on the condition that the companies divest two product lines.
The Chinese approval was the last in a series of regulatory approvals required to close the acquisition.